当前位置:循环首页>正文

[ESC2009]ACCOMPLISH的影响及单片复方制剂(SPC)在临床中的应用--Dahlof教授专访

作者:国际循环网   日期:2009/9/3 19:00:00

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

ACCOMPLISH研究是第一个将固定剂量复合制剂(SPC)RAAS/CCB同RAAS/利尿剂用于高血压或高心血管事件风险的患者效果比较的试验,您认为这个研究是否会推动单片复方制剂(single-pill combination,SPC)在临床高血压治疗中的广泛应用呢?您认为ACCOMPLISH研究对JNC8及ESC/ESH高血压指南对于SPC的临床应用将会有何影响?


International Circulation:  Finally, I know that there are side effects with amlodipine mono therapies so how significant is it? If there is a real improvement when we have the combination together with amlodipine?

国际循环:最后,我知道氨氯地平单一疗法有一定的不良反应,这到底有多大意义?与氨氯地平联合是否真的有所改善?

Dahlof:  I mean the improvement is not only with the figures, the improvement is also that you have less side effects and I think that it one advantage that many forget.  Amlodipine has this advantage of ankle edema when you give it together of a blocker of renin angiotensin system you can half or even two thirds the number of patients who have problems with ankle edema.  So I think it is a real advantage that you have more efficacious medication that is based on a very good mechanistic complimentary action of the two drugs in addition to being better tolerated than mono therapy can be especially mono therapy of calcium channel blocker.  


 Dahlof:我说的改善不单指临床数据,同时可以减少不良反应,这也是常被忽略的。氨氯地平与肾素血管紧张素拮抗剂联用,可缓和1/2至2/3患者的踝部水肿。这是基于两种药物机制的有益互补,获得比单一疗法尤其是钙通道阻断剂单一疗法更好的耐受性。

上一页  [1]  [2]  [3]  [4]  

版面编辑:杨新象  责任编辑:张衡



KYOTO HEARTDahlof倍博特阿利吉仑

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530